SCHEMBL1085604

SCHEMBL1085604

Nc1ccncc1[N+](=O)[O-]

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
MAPT P10636 4/20 0.57
TDP1 Q9NUW8 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.48
ALOX15 P16050 1/20 0.48
HTT P42858 2/20 0.46
RAB9A P51151 1/20 0.46
TSHR P16473 2/20 0.46
NPSR1 Q6W5P4 1/20 0.45
GAA P10253 2/20 0.43
GSK3B P49841 1/20 0.43
HASPIN Q8TF76 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29618079 1.00 ALDH1A1 (0.57) ALDH1A1MAPTTDP1MEN1KMT2A
Methane SCHEMBL28322282 0.98 ALDH1A1 (0.55) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL1284068 0.83 MAPT (0.53) ALDH1A1MAPTTDP1MEN1KMT2A
Ethoxycarbonyl Group SCHEMBL28109244 0.82 MAPT (0.43) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL2219710 0.81 ALDH1A1 (0.48) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL8568179 0.80 ALDH1A1 (0.53) ALDH1A1MAPTMEN1KMT2APOLB
Ethylene SCHEMBL27749127 0.77 ALDH1A1 (0.50) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL3577339 0.76 MAPT (0.52) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL319309 0.75 ALDH1A1 (0.49) ALDH1A1MAPTMEN1KMT2APOLB
SCHEMBL227454 0.75 ALDH1A1 (0.49) ALDH1A1MAPTTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924347-A Preparation method of monosulfur organosilane coupling agent 江西宏柏新材料股份有限公司 2024-04-26 CN claimed
CN-115184486-B Method for detecting diaminopyridine phosphate related substances by high performance liquid chromatography 河北一品生物医药有限公司 2023-07-18 CN claimed
CN-114682102-B Reverse osmosis membrane and preparation method thereof 沃顿科技股份有限公司 2023-06-27 CN claimed
CN-114432900-B Preparation method of anti-pollution composite reverse osmosis membrane and anti-pollution composite reverse osmosis membrane prepared by same 沃顿科技股份有限公司 2023-03-21 CN claimed
CN-115184486-A Method for detecting related substances of diaminopyridine phosphate by high performance liquid chromatography 河北一品生物医药有限公司 2022-10-14 CN claimed
CN-114682102-A Reverse osmosis membrane and preparation method thereof 沃顿科技股份有限公司 2022-07-01 CN claimed
CN-114432900-A Preparation method of anti-pollution composite reverse osmosis membrane and anti-pollution composite reverse osmosis membrane prepared by same 沃顿科技股份有限公司 2022-05-06 CN claimed
CN-114315706-A Synthetic method of 3, 4-diaminopyridine 河北一品生物医药有限公司 2022-04-12 CN claimed
CN-103342621-B Method for performing catalytic synthesis of diphenylamine derivatives by using bisphenol copper salt HEILONGJIANG UNIVERSITY (CN) 2014-10-29 CN claimed
CN-103342621-A Method for performing catalytic synthesis of diphenylamine derivatives by using bisphenol copper salt UNIV HEILONGJIANG 2013-10-09 CN claimed
CN-101343366-A Nano-laminal compound with regular array of pyridine and its derivant, and preparation thereof UNIV SHANGHAI (CN) 2009-01-14 CN claimed
CN-1660842-A Preparation of 4-hydroxy-3-nitro-2(1h)-pyridone from 2-hydroxy-3-cyano-4-methoxypyridine AVENTIS PHARMA INC (US) 2005-08-31 CN claimed
CN-1394859-A Intermediate for preparing cyclopentane formamide compound and preparation method thereof AVENTIS PHARMACEUTICAL CO (US) 2003-02-05 CN claimed
CN-1240445-A Preparation method of [ 1S- [1a,2b,3b,4a ] ] -4- [ 7- [ [ 1- (3-chloro-2-thienyl) methyl ] propyl ] amino-3H-imidazo [4, 5-b ] pyridin-3-yl ] -N-ethyl-2, 3-dihydroxycyclopentanecarboxamide RHONE POULENC RORER PHARMA (US) 2000-01-05 CN claimed
US-20260116878-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF BIOSPLICE THERAPEUTICS INC (US) 2026-04-30 US disclosed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
US-12453708-B2 Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2025-10-28 US disclosed
EP-0149537-B1 PROCESS FOR THE SYNTHESIS OF AMINONITROPYRIDINES ELI LILLY AND COMPANY (US) 1988-07-13 EP disclosed
US-4552967-A Process for the synthesis of intermediates in the preparation of diaminopyridines ELI LILLY AND COMPANY (US) 1985-11-12 US disclosed
EP-0149537-A2 Process for the synthesis of aminonitropyridines ELI LILLY AND COMPANY (US) 1985-07-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12453708-B2 Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases KEAP1, GOT2, COL1A1 ALDH1A1 106/4885MAPT 3640/4885TDP1 1161/4885
US-20260116878-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A ALDH1A1 1879/4885MAPT 1206/4885TDP1 3553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.